Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,020	$ 9,038
Prepaid clinical trial costs	0	2,747
Prepaid expenses and other	1,210	1,034
Total current assets	2,230	13,535
Operating right-of-use assets, net	26	7,846
Property and equipment, net	4,236	4,214
Other Assets	936	2,136
Total assets	7,428	27,731
Current liabilities:
Accounts payable	9,295	27,765
Deferred accounts payable to Supplier	7,862	0
Operating lease liabilities, current	7,792	746
Accrued compensation and related benefits	890	1,090
Accrued clinical trial related costs	360	7,231
Accrued expenses and other	1,490	1,078
Note Payable	10,785	0
Deferred revenue - Healios	150	0
Warrant liability	0	534
Total current liabilities	38,624	38,444
Operating lease liabilities, non-current	0	7,939
Stockholders’ equity:
Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at September 30, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value; 600,000,000 shares authorized with 26,758,431 and 17,986,147 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	27	18
Additional paid-in capital	642,754	632,009
Accumulated deficit	(680,384)	(655,878)
Accumulated other comprehensive income	1,208	0
Total stockholders’ deficit	(36,395)	(23,851)
Total liabilities and stockholders’ equity	7,428	27,731
Affiliated Entity [Member]
Current assets:
Accounts receivable from Healios	0	716
Current liabilities:
Advance from Healios	$ 5,199	$ 5,199